We attempted to optimize some of the variables involved in the in vitro culturing of Plasmodium falciparum. Irrespective of the isolates used, suspension cultures in glucose-enriched RPMI-1640 medium buffered with TES yielded about twice the amount of parasites than could be obtained from static, thin-layer cultures with HEPES-buffered RPMI-1640 without additional glucose. In suspension cultures, methylcellulose (1 mg/ml) was added to protect the erythrocytes. In addition the erythrocytes were found to be more suitable for culturing P. falciparum when stored as a concentrate in saline-adenine-glucose than as whole blood in citrate-phosphate-dextrose. With a cloned isolate of P. falciparum (Tak9/clone 96) a further stimulation of the final parasitemia could be achieved by supplementing the medium with hypoxanthine (50 micrograms/ml) and reduced glutathione (600 micrograms/ml). Moreover, we identified hypoxanthine and glutathione as two of the factors critical for the ability of human serum to support the growth of the parasites. These modifications give a two- to four-fold increase in the final parasitemia over the original Trager-Jensen culture method, thus allowing more parasites to be isolated for biochemical studies.

SummarySamples taken at various stages of preparation of intermediate purity factor VIII concentrate were assayed for factor VIII coagulant activity (VIII:C), factor VIII coagulant antigen (VIIIC: Ag) and factor VIII related antigen (VIIIR: Ag). The antigen results were used to assess mechanical loss during fractionation as these markers are relatively stable. In contrast VIII:C is sensitive to both mechanical and inactivation losses.The major loss of factor VIII occurred during the cryoprecipitation and extraction step and was due to both mechanical loss and inactivation. Losses before and after this step were largely due to inactivation of the factor VIII.Assay of VIIIR: Ag in concentrates presented problems and a modified technique is suggested.

Cryoprecipitation is commonly used as the primary step in the preparation of clinical factor VIII concentrates; yet recovery is usually very low. Much of this loss is due to poor temperature control and a process of continuous plasma thawing has been designed to overcome this. A substantial improvement has resulted, with an increase in both yield and purity of factor VIII:C of over 50% in comparison to a conventional batch thaw process.

Cryoprecipitation is commonly used as the primary step in the preparation of clinical factor VIII concentrates; yet recovery is usually very low. Much of this loss is due to poor temperature control and a process of continuous plasma thawing has been designed to overcome this. A substantial improvement has resulted, with an increase in both yield and purity of factor VIII :C of over 50% in comparison to a conventional batch thaw process.

The stability of VIII:C was investigated by monitoring samples taken at different points from a routine process for the manufacture of factor VIII concentrate and by examining the stabilising influence of a number of product formulations. Loss of VIII:C over process-finishing procedures (formulation, 0.22 micron filtration, dispensing) was associated with a citrate-induced inactivation which could be prevented by controlling the ionised calcium concentration of the solution. These results were obtained using a one-stage clotting assay but were not observed using a two-stage assay. No evidence for activation was found in vitro (e.g. by FPA generation and VIII:C stability) and the yield increase suggested by the one-stage assay was supported by results from a controlled clinical evaluation.